Showing results (711-720 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|November 27, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumorsJeffrey R Infante, Silvia Novello, Wen Wee Ma, et al.
Investigational New Drugs|November 27, 2012
Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome systemJenny Felth, Karolina Lesiak-Mieczkowska, Padraig D'Arcy, et al.
Investigational New Drugs|November 19, 2013
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumorsWoondong Jeong, Sook Ryun Park, Annamaria Rapisarda, et al.
Investigational New Drugs|November 19, 2013
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous dosesWolfgang Uhl, Michael Zühlsdorf, Thomas Koernicke, et al.
Investigational New Drugs|November 8, 2014
Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomasAnne-Charlotte Dubbelman, Hilde Rosing, Cynthia Nijenhuis, et al.
Investigational New Drugs|November 6, 2014
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumorsNuttapong Ngamphaiboon, Grace K Dy, Wen Wee Ma, et al.
Investigational New Drugs|August 26, 2014
Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitorsFlorian Ewald, Dominik Nörz, Astrid Grottke, et al.
Investigational New Drugs|August 22, 2025
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013-2021Zhizhou Liang, Yu Yang, Yichen Zhang, et al.
Investigational New Drugs|May 22, 2026
A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancerFengting Yan, Marcia Cruz-Correa, Jennifer Specht, et al.
Investigational New Drugs|April 14, 2026
A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumorsTakafumi Koyama, Kan Yonemori, Jun Sato, et al.
Pageof 372